Metabolic & Cardiometabolic
ezetimibe treats sitosterolemia
In plain terms: Does ezetimibe treat the rare disease sitosterolemia?
Strong support Metabolic & Cardiometabolic 💰 Industry COI noted
Part of: 💊 ezetimibe
RefutedContestedStrong support
consensus score 0.91
Yes, it blocks the plant-cholesterol over-absorption that defines the disease and is the treatment of choice.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
28 support 0 contradict 0 tested null 2 mixed · 30 sources, 28 independent groups
What the evidence shows
Ezetimibe is the drug of choice for sitosterolemia (ABCG5/G8 plant-sterol hyperabsorption) - it blocks the NPC1L1-mediated hyperabsorption that defines the disease. Its one definitive non-LDL indication. (Clinically relevant mainly where statin-poorly-responsive hypercholesterolemia + xanthomas raise suspicion of sitosterolemia.)
The evidence (30)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Castellanos 2024 · Clin Investig Arterioscler | observational | supports | moderate | First Colombian familial sitosterolemia cases; symptomatic ABCG8 patient responded to ezetimibe therapy. |
| Do TTM et al 2025 · study_type: observational | observational | supports | low | 14 Vietnamese children with sitosterolemia; 10 with persistent elevated TC/LDL-C after dietary trial were started on ezetimibe or cholestyramine; among 8 continuing >3 months, median TC decreased 54.9% and LDL-C 67.3%. |
| Umapathy 2025 · J Assoc Physicians India | observational | supports | moderate | Four ABCG5/ABCG8-confirmed sitosterolemia patients responded to low-plant-sterol diet plus ezetimibe. |
| Naeem WB et al 2025 · study_type: observational | observational | supports | low | 2 siblings from consanguineous Pakistani family with novel homozygous ABCG5 variant and hereditary hemolytic anemia; treatment with ezetimibe resulted in significant decrease in sitosterol and LDL-cholesterol. |
| Kassaie H et al 2025 · study_type: observational | observational | supports | low | 15-year-old with homozygous ABCG5 variant and 13 years of therapy-resistant hypercholesterolemia; after introducing dietary phytosterol restriction and ezetimibe, lipid levels normalized within 4 months. |
| Trehan M et al 2026 · study_type: observational | observational | supports | moderate | Case series of 4 patients (age 10-29) with sitosterolemia-related hemolytic anemia; 3 placed on ezetimibe + low-sterol diet showed significant hemoglobin improvement, 4th just started. |
| Huang 2025 · Translational Pediatrics | observational | supports | low | Long-term follow-up of pediatric sitosterolemia: ezetimibe plus dietary plant-sterol restriction lowered phytosterols/LDL-C. |
| Donnelly A et al 2026 · study_type: observational | observational | supports | low | 9-year-old girl with lipid keratopathy from sitosterolemia; cholesterol/lipid profile normalized following dietary restriction plus ezetimibe 10mg + atorvastatin 10mg daily. |
| Wu SF et al 2026 · study_type: observational | observational | supports | low | 3-year-old with novel compound heterozygous ABCG5 mutation and elevated plasma phytosterols; ezetimibe plus low-plant-sterol diet improved xanthomas and biochemical parameters. |
| Gu 2024 · Lipids Health Dis | observational | supports | moderate | Chinese pediatric sitosterolemia cohort: ezetimibe is the cornerstone pharmacotherapy alongside low-sterol diet. |
| Lutjohann 2008 2008 · Int J Clin Pract | observational | supports | moderate | [FT-verified] 2yr open-label ext sitosterol -43.9% campesterol -50.8% apoB -10.1%; sustained |
| Coutinho JGV et al 2025 · study_type: observational | observational | mixed | moderate | 21-year follow-up of compound heterozygous ABCG5 sitosterolemia patient on low-sterol diet + ezetimibe: resolution of splenomegaly/thrombocytopenia, stabilized xanthomas, no cardiovascular events, but plasma campesterol/sitosterol remained |
| Salen 2004 · Circulation | RCT | supports | high | [FT-verified] Multicenter Sitosterolemia RCT n=37 4:1; Merck-funded COI; airtight NPC1L1 for disease-defining indication |
| Wu 2026 · J Med Case Rep | observational | supports | low | Compound-heterozygous ABCG5 sitosterolemia case managed with ezetimibe and diet. |
| Burke E et al 2026 · study_type: observational | observational | supports | low | 7-year-old girl with sitosterolemia (ABCG5) confirmed after partial statin response; treated with dietary restriction of plant sterols and ezetimibe; no coronary calcification on follow-up CT. |
| Gómez SIN et al 2026 · Research Square | observational | supports | low | 8-year-old boy, compound heterozygous ABCG8 variants; treatment with ezetimibe and plant-sterol-restricted diet initiated with a favorable biochemical response. |
| Gamage D et al 2025 · study_type: observational | observational | supports | low | Case series of 4 Australian children (18mo-18yr) with sitosterolemia presenting with xanthomas/hematologic/lipid abnormalities; all managed with dietary adjustments and ezetimibe resulting in improvement of lipid and haematological profiles |
| Uzunyayla 2025 · J Clin Lipidol | observational | supports | moderate | Ezetimibe raised platelet count (58k to 140k) in an ABCG5-homozygous child with sitosterolemic thrombocytopenia. |
| Matta A et al 2026 · study_type: observational | observational | supports | low | Case report/review: 'good response to ezetimibe therapy' is a diagnostic hallmark distinguishing sitosterolemia from FH; diet + ezetimibe described as mainstay treatment. |
| Maidman SD et al 2025 · study_type: observational | observational | supports | low | Patient with digenic overlap of heterozygous FH and heterozygous sitosterolemia and elevated cholesterol absorption indices; treatment with ezetimibe 10mg daily resulted in a dramatic reduction in LDL cholesterol. |
| Patel PS et al 2025 · study_type: observational | observational | supports | moderate | 3 siblings with sitosterolemia (thrombocytopenia presentation); ezetimibe 10mg/day + diet reduced sitosterol 40-51% and campesterol 40-66% over 3-6 months, with platelet counts rising 22-39%. |
| Alves 2025 · J Clin Lipidol | observational | supports | moderate | 16 new Iberoamerican sitosterolemia cases; ezetimibe central to management once correctly distinguished from FH. |
| Hummadi A et al 2025 · study_type: observational | observational | supports | low | Saudi family with concurrent LDLR and ABCG8 mutations (digenic FH+sitosterolemia); proband responded remarkably to ezetimibe monotherapy, while his children (different genotype burden) needed combination therapy. |
| Mustajoki, et al. 2026 · (case) | observational | supports | low | Case report homozygous ABCG8 phytosterolemia eze+rosuva+diet corrected dyslipidemia. n=1 |
| Warang P et al 2026 · study_type: observational | observational | mixed | moderate | 4 patients with sitosterolemia + hemolytic anemia; ezetimibe 10mg/day x6mo effectively reduced plasma phytosterols (stigmasterol/sitosterol) but failed to normalize hemoglobin or reduce overhydrated RBC populations. Case series. |
| Del Castillo 2024 · Blood Advances | observational | supports | moderate | Two ABCG5 sitosterolemia pedigrees treated with dietary restriction plus ezetimibe; xenosterols fell, addressing the underlying lipid disorder. |
| Othman 2014 · J Clin Lipidol | observational | supports | moderate | [FT-verified] Eze cut plant sterols + raised platelets/lowered MPV; consistent direction |
| Leao 2025 · Arch Endocrinol Metab | observational | supports | low | ABCG8-homozygous patient had excellent response to plant-fat-restricted diet plus ezetimibe after years of misdiagnosis. |
| Waluś-Miarka M et al 2026 · study_type: observational | observational | supports | low | First Polish sitosterolemia family; 19-year-old proband with markedly elevated phytosterols; ezetimibe + low-plant-sterol diet resulted in improvement of lipid profile. |
| Anum et al 2025 · study_type: observational | observational | supports | low | Adult male with novel ABCG8 variant combination presenting with hemolytic anemia/macrothrombocytopenia; treated with statin, ezetimibe, and low-sterol diet; plasma sterol levels improved after 9 months. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.